MiNK Therapeutics, Inc. (NASDAQ:INKT) Given Consensus Rating of “Hold” by Analysts

MiNK Therapeutics, Inc. (NASDAQ:INKT) has been given an average recommendation of “Hold” by the five brokerages that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, one has assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $35.00.

Separately, Wall Street Zen upgraded MiNK Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 19th.

Institutional Inflows and Outflows

An institutional investor recently raised its position in MiNK Therapeutics stock. Geode Capital Management LLC increased its position in MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the quarter. Geode Capital Management LLC owned 0.30% of MiNK Therapeutics worth $159,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 2.87% of the company’s stock.

MiNK Therapeutics Trading Up 29.3%

INKT opened at $13.51 on Wednesday. The company has a market cap of $63.36 million, a P/E ratio of -4.46 and a beta of 0.35. The business’s 50-day moving average price is $11.58 and its 200-day moving average price is $12.77. MiNK Therapeutics has a 12 month low of $6.34 and a 12 month high of $76.00.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.